James J. Lah

Active 1990–2026

166
Papers
23,815
Citations
84
h-index
142
i10-index

Citations

Citations per year for James J. Lah1993: 1 citations1995: 2 citations1996: 1 citations1997: 7 citations1998: 14 citations1999: 16 citations2000: 14 citations2001: 15 citations2002: 32 citations2003: 32 citations2004: 35 citations2005: 31 citations2006: 51 citations2007: 52 citations2008: 64 citations2009: 75 citations2010: 101 citations2011: 177 citations2012: 217 citations2013: 228 citations2014: 258 citations2015: 233 citations2016: 295 citations2017: 256 citations2018: 321 citations2019: 738 citations2020: 1,021 citations2021: 1,234 citations2022: 1,135 citations2023: 953 citations2024: 1,540 citations2025: 808 citations2026: 16 citations1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,921 citing papers, 30.2% of this breakdownChina: 1,205 citing papers, 9.3% of this breakdownUnited Kingdom: 1,052 citing papers, 8.1% of this breakdownGermany: 746 citing papers, 5.8% of this breakdownCanada: 520 citing papers, 4% of this breakdownAustralia: 427 citing papers, 3.3% of this breakdownItaly: 407 citing papers, 3.1% of this breakdownFrance: 380 citing papers, 2.9% of this breakdownSpain: 373 citing papers, 2.9% of this breakdownSweden: 353 citing papers, 2.7% of this breakdownNetherlands: 340 citing papers, 2.6% of this breakdownJapan: 272 citing papers, 2.1% of this breakdown
0%30.2%Other 23%

Fields

  • Medicine45.4%
  • Neuroscience24.1%
  • Biochemistry, Genetics and Molecular Biology23.4%
  • Immunology and Microbiology1.7%
  • Chemistry1.2%
  • Computer Science1%
  • Other3.2%

Topics

  • Alzheimer's disease research and treatments15.4%
  • Neuroinflammation and Neurodegeneration Mechanisms8.3%
  • Dementia and Cognitive Impairment Research4.3%
  • Tryptophan and brain disorders2.3%
  • Amyotrophic Lateral Sclerosis Research2.1%
  • Bioinformatics and Genomic Networks2.1%
  • Other65.5%

Coauthors

All papers

Open in search
  1. Variant of TREM2 Associated with the Risk of Alzheimer's Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 2,620

  2. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James J. Lah, Allan I. Levey, Nicholas T. Seyfried - Nature Medicine 2020 cited by 1,060

  3. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert C. Green, Ekaterina Rogaeva, Peter St George‐Hyslop, Steven E. Arnold, Robert C. Barber, Thomas G. Beach, Eileen H. Bigio, James D. Bowen, Adam Boxer, James R. Burke, Nigel J. Cairns, Chris Carlson, Regina M. Carney, Steven L. Carroll, Helena C. Chui, David G. Clark, Jason J. Corneveaux, Carl W. Cotman, Jeffrey L. Cummings, Charles DeCarli, Steven T. DeKosky, Ramon Diaz‐Arrastia, Malcolm Dick, Dennis W. Dickson, William G. Ellis, Kelley M. Faber, Kenneth B. Fallon, Martin R. Farlow, Steven H. Ferris, Matthew P. Frosch, Douglas Galasko, Mary Ganguli, Marla Gearing, Daniel H. Geschwind, Bernardino Ghetti, John R. Gilbert, Sid Gilman, Bruno Giordani, Jonathan D. Glass, John H. Growdon, Ronald L. Hamilton, Lindy E. Harrell, Elizabeth Head, Lawrence S. Honig, Christine M. Hulette, Bradley T. Hyman, Gregory A. Jicha, Lee‐Way Jin, Nancy Johnson, Jason Karlawish, Anna Karydas, Jeffrey Kaye, Ronald Kim, Edward H. Koo, Neil W. Kowall, James J. Lah, Allan I. Levey, Andrew P. Lieberman, Oscar L. López, Wendy J. Mack, Daniel Marson, Frank Martiniuk, Deborah C. Mash, Eliezer Masliah, Wayne C. McCormick, Susan M. McCurry, Andrew McDavid, Ann C. McKee, Marsel Mesulam, Bruce L. Miller and 55 more - Nature Genetics 2011 cited by 2,014

  4. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher H. van Dyck, Lawrence S. Honig, Raquel Sánchez‐Valle, William S. Brooks, Serge Gauthier, Douglas Galasko, Colin L. Masters, Jared R. Brosch, Ging‐Yuek Robin Hsiung, Suman Jayadev, Maïté Formaglio, Mario Masellis, Roger Clarnette, Jérémie Pariente, Bruno Dubois, Florence Pasquier, Clifford R. Jack, Robert A. Koeppe, Peter J. Snyder, Paul Aisen, Ronald G. Thomas, Scott Berry, Barbara Wendelberger, Scott W. Andersen, Karen C. Holdridge, Mark A. Mintun, R. Yaari, John R. Sims, Monika Baudler, Paul Delmar, Rachelle S. Doody, Paulo Fontoura, Caroline Giacobino, Geoffrey A. Kerchner, Randall J. Bateman, the Dominantly Inherited Alzheimer Network–Trials Unit, Maïté Formaglio, Susan L. Mills, Jérémie Pariente, Christopher H. van Dyck - Nature Medicine 2021 cited by 365

  5. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease

    Authors: , , , , , , , , , , , , , - Science Advances 2020 cited by 393

  6. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mathias Jucker, John C. Morris, Tammie L.S. Benzinger, Blaine R. Roberts, Randall J. Bateman, Anne M. Fagan, Nicholas T. Seyfried, Allan I. Levey, the Dominantly Inherited Alzheimer Network, Jonathan Vöglein, Ricardo Allegri, Patricio Chrem Méndez, Ezequiel Surace, Sarah Berman, Snežana Ikonomović, Neelesh K. Nadkarni, Francisco Lopera, Laura Ramírez, David Aguillón, Yudy Milena Leon, Cláudia Ramos, Diana Alzate, Ana Baena, Natalia Londono, Sonia Moreno, Christoph Laske, Elke Kuder-Buletta, Susanne Gräber‐Sultan, Oliver Preische, Anna Hofmann, Kensaku Kasuga, Yoshiki Niimi, Kenji Ishii, Michio Senda, Raquel Sánchez‐Valle, Pedro Rosa‐Neto, Nick C. Fox, David M. Cash, Jae‐Hong Lee, Jee Hoon Roh, Meghan Riddle, William Menard, Courtney Bodge, Mustafa Surti, Leonel Tadao Takada, Víctor Javier Sánchez-González, Maribel Orozco-Barajas, Alison Goate, Alan E. Renton, Bianca Esposito, Jacob Marsh, Carlos Cruchaga, María Victoria Fernández, Gina Jerome, Elizabeth Herries, Jorge J. Llibre‐Guerra, William S. Brooks, Jacob Bechara, Jason Hassenstab, Erin Franklin, Allison Chen, Charles D. Chen, Shaney Flores, Nelly Friedrichsen, Nancy Hantler, Russ C. Hornbeck, Steve Jarman, Sarah Keefe, Deborah Koudelis, Parinaz Massoumzadeh and 25 more - Nature Medicine 2023 cited by 173

  7. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis

    Authors: , , , , , , , , , , , , , , , , - Nature Genetics 2021 cited by 401

  8. Evidence for brain glucose dysregulation in Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2017 cited by 520

  9. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Scientific Data 2018 cited by 605

  10. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease

    Authors: , , , , , , , , , , - Molecular Neurodegeneration 2018 cited by 461

  11. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roger N. Rosenberg, Charles L. White, Isidró Ferrer, Albert Lladó, Manuela Neumann, Hans A. Kretzschmar, Christine M. Hulette, Kathleen A. Welsh‐Bohmer, Bruce L. Miller, Ainhoa Alzualde, Adolfo López de Munain, Ann C. McKee, Marla Gearing, Allan I. Levey, James J. Lah, John Hardy, Jonathan D. Rohrer, Tammaryn Lashley, Ian R. Mackenzie, Howard Feldman, Ronald L. Hamilton, Steven T. DeKosky, Julie van der Zee, Samir Kumar‐Singh, Christine Van Broeckhoven, Richard Mayeux, Jean Paul Vonsattel, Juan C. Troncoso, Jillian J. Kril, John B. Kwok, Glenda M. Halliday, Thomas D. Bird, Paul G. Ince, Pamela J. Shaw, Nigel J. Cairns, John C. Morris, Catriona McLean, Charles DeCarli, William G. Ellis, Stefanie H. Freeman, Matthew P. Frosch, John H. Growdon, Daniel P. Perl, Mary Sano, David A. Bennett, Julie A. Schneider, Thomas G. Beach, Eric M. Reiman, Bryan K. Woodruff, Jeffrey L. Cummings, Harry V. Vinters, Carol A. Miller, Helena C. Chui, Irina Alafuzoff, Päivi Hartikainen, Danielle Seilhean, Douglas Galasko, Eliezer Masliah, Carl W. Cotman, MJ Tuñón, Mònica Martínez, David G. Muñoz, Steven L. Carroll, Daniel Marson, Peter Riederer, Nenad Bogdanović, Gerard D Schellenberg, Håkon Håkonarson, John Q. Trojanowski, Virginia M.‐Y. Lee - Nature Genetics 2010 cited by 609

  12. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease

    Authors: , , , , , , , , , , , , , , , , - Cell Systems 2016 cited by 536

  13. Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age

    Authors: , , , , , , , , , , , , , , - Nature Communications 2019 cited by 234

  14. Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain

    Authors: , , , , , , , , , , , , , , , , , - Nature Neuroscience 2020 cited by 169

  15. A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease

    Authors: , , , , , , , , , , , , - Alzheimer s & Dementia Translational Research & Clinical Interventions 2021 cited by 126

  16. Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer’s Disease

    Authors: , , , , , , , , , , , , , - Cell Reports 2019 cited by 203

  17. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease

    Authors: , , , , , , , , , - Molecular Neurodegeneration 2023 cited by 74

  18. Brain proteome-wide association study implicates novel proteins in depression pathogenesis

    Authors: , , , , , , , , , , , , , , , , , , - Nature Neuroscience 2021 cited by 174

  19. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pálmi V. Jónsson, Sigurbjörn Björnsson, Jón Snædal, Kari Stefansson - Nature Genetics 2015 cited by 332

  20. CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Aging 2022 cited by 102

  21. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Donna M. Willcock, Allan I. Levey, James J. Lah, Junmin Peng - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 342

  22. Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease

    Authors: , , , , , , - Scientific Data 2018 cited by 268

  23. Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

    Authors: , , , , , , , , - Molecular Neurodegeneration 2018 cited by 263

  24. Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michelle E. Ehrlich, Bin Zhang, Stephen R. Salton, Eric E. Schadt - Nature Communications 2020 cited by 189